Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 973 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Embolism Clear all
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Jul 21, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 21, 2026, 9:49 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

NCT01011374
View directory record Official record
Conditions
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions
ranibizumab (Lucentis)
Drug
Lead sponsor
Retina Associates of Cleveland, Inc
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Jul 21, 2026, 9:49 PM EDT
Recruiting Not applicable Interventional

The Fourth Left Atrial Appendage Occlusion Study

NCT05963698
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Interventions
WATCHMAN device
Device
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
50
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 9:49 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jul 21, 2026, 9:49 PM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 9:49 PM EDT
Terminated Phase 1 Interventional

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

NCT03790852
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 21, 2026, 9:49 PM EDT
Completed No phase listed Observational Results available

Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures

NCT02037607
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
1 Month to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 21, 2026, 9:49 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

NCT00709904
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jul 21, 2026, 9:49 PM EDT
Not listed Phase 1 Interventional

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311
View directory record Official record
Conditions
Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Dexamethasone
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 9:49 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

NCT02744833
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
GMI-1271, Enoxaparin Sodium (Lovenox®)
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 21, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Jul 21, 2026, 9:49 PM EDT
Not listed Phase 3 Interventional

Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

NCT00934427
View directory record Official record
Conditions
Raynaud Disease
Interventions
0.9% nitroglycerin in TAM cream, vehicle cream
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Redwood City, California • Farmington, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Jul 21, 2026, 9:49 PM EDT
Completed No phase listed Observational Results available

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

NCT01411696
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
dexamethasone intravitreal implant 0.7 mg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Jul 21, 2026, 9:49 PM EDT
Recruiting Phase 2 Interventional

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

NCT04295486
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Aspirin
Drug
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
5,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 21, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

NCT01977456
View directory record Official record
Conditions
Stroke, Brain Infarction
Interventions
Eptifibatide
Drug
Lead sponsor
Arthur Pancioli
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Edgewood, Kentucky • Florence, Kentucky • Fort Thomas, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Jul 21, 2026, 9:49 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

NCT00211354
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Jul 21, 2026, 9:49 PM EDT
Completed Not applicable Interventional Results available

Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention

NCT01802554
View directory record Official record
Conditions
Depressive Symptoms, Inflammation
Interventions
Pleasant Events Program (PEP), Information Support (IS)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Jul 21, 2026, 9:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effects of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers

NCT05272475
View directory record Official record
Conditions
Coagulation Disorder
Interventions
Chamomile Tea, Chamomile Extract Capsule
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Jul 21, 2026, 9:49 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT00500045
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
nicotinic acid
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jul 21, 2026, 9:49 PM EDT
Terminated No phase listed Observational

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

NCT01875770
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 21, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
pegaptanib sodium injection
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Jul 21, 2026, 9:49 PM EDT
Completed No phase listed Observational Results available

FlowTriever for Acute Massive Pulmonary Embolism (FLAME)

NCT04795167
View directory record Official record
Conditions
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Interventions
Not listed
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Atlanta, Georgia • Royal Oak, Michigan • Southfield, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Jul 21, 2026, 9:49 PM EDT
Completed No phase listed Observational

Evaluation of ST2 and IL-33 in Patients Presenting to the Emergency Department With Trouble Breathing

NCT00707811
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma, Pulmonary Embolism, Pneumonia, Congestive Heart Failure
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 21, 2026, 9:49 PM EDT